The Board of Directors of Wanbury Limited, in their meeting held on May 29, 2026, approved the audited financial results for the quarter and year ended March 31, 2026. For the quarter ended March 31, 2026, the company reported a revenue from operations of ₹16,457.86 Lakhs, compared to ₹16,244.75 Lakhs in the previous quarter and ₹17,199.95 Lakhs in the corresponding quarter of the previous year. The Profit After Tax (PAT) for the quarter stood at ₹2,170.49 Lakhs, compared to ₹1,575.90 Lakhs in the previous quarter and ₹2,025.64 Lakhs in the same quarter last year.

Wanbury Limited is a prominent pharmaceutical company with a significant focus on research, manufacturing, and marketing of active pharmaceutical ingredients (APIs) and finished dosage formulations. The company operates two USFDA-approved manufacturing facilities located in Tanuku, Andhra Pradesh, and Patalganga, Maharashtra. A notable operational update from 2026 is that the Patalganga facility successfully cleared an inspection by the Ministry of Food and Drug Safety (MFDS) of South Korea in April 2026 with zero observations.